Shilpa Medicare Ltd Q2 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/lx5wy61jl4q0yli8qj0bb5ll.pdf

Key Takeaways


The Quarter: What Drove the Breakthrough

Keshav Bhutada: "The current quarter marks a very big breakthrough for us. We recorded highest quarterly EBITDA, and the excitement is not only to share another set of results, but to share the momentum, the confidence and the direction that the company is focusing on ensuring better asset utilization."

NorUDCA: The First NCE, and a Global Ambition

Keshav Bhutada: "I think we don't want to have a lot of partners who inturn would compete among each other. So it's more a strategic partnering what we have done for the product."

Pipeline: What Is Coming, and When

Near-term commercial triggers

ProductTriggerTimeline
Ursodeoxycholic AcidCommercial supplies startQ3 FY26
NorUDCA APICommercial supplies startQ3 FY26
NCE program (big pharma partner)First product commercial suppliesQ4 FY26
Rotigotine transdermal patchU.S. submission; approvalQ3 FY26; Q4 FY26
Ondansetron long-acting injectionIndia filing; launchQ4 FY26; next FY
SemaglutidePV campaign complete; filingQ4 FY26; H1 FY27
Lanthanum Dioxycarbonate (Unicycive)Block commissioning; commercial launchQ3 FY26; next FY

Medium-term pipeline milestones

Alpesh Dalal: "I'm happy to report that the PAT that we have achieved in the first half has surpassed our full year PAT in FY '25, which was at INR78 crores."

European Strategy: Complex, Not Commodity

Keshav Bhutada: "if you just go with me-too generics, then there is a big competition, and you cannot get market share. So in Europe, if we really want to grow and increase our market share we need to focus more on complex generics and differentiated early non-infringing formulations."

Financial Health: Margins, Returns, and Capex


Unanswered Questions


Guidance & Commitments

CommitmentSpecificsTimeline
API business growthDouble-digit YoY growthOngoing
Tranexamic Acid capacityAchieve full utilization of current capacityCurrent year
Tranexamic Acid expansionCommission additional 100 MT capacityNext financial year
Ursodeoxycholic AcidStart commercial suppliesQ3 FY26
NorUDCA APIStart commercial supplies; meaningful contributionQ3 FY26; next FY
First NCE product (big pharma)Start commercial suppliesQ4 FY26
Rotigotine patchU.S. submission; approvalQ3 FY26; Q4 FY26
SemaglutideComplete PV campaign; fileQ4 FY26; H1 FY27
Lanthanum DioxycarbonateCommission dedicated block; commercial launchQ3 FY26; next FY
Ondansetron long-acting injectionFile in India; launchQ4 FY26; next FY
OLC (Unicycive)Approval; commercialization revenueFY26; second half next FY
Recombinant Human AlbuminStart European Phase IIIQ4 FY26
NivolumabStart Phase I/III India trialQ4 FY26
Two NBE programsEnter Phase I human studiesFY27
First ADC biosimilarEnter human studiesFY27
AfliberceptLaunch (subject to clinical success)FY27
Androgenic AlopeciaStart Phase IIIH1 next FY
Peptide project with MNCCommercializationCalendar 2027
Interest outgoRemain at current levelsOngoing

Key Metrics

MetricQ2 FY26
Revenue₹372 cr, +7% YoY; highest ever quarterly revenue
H1 FY26 revenue₹700 cr, +8% YoY
Gross margin72% for the quarter, 74% for H1; improved despite lower CDMO and licensing contribution
EBITDA₹110 cr, +21% YoY vs ₹91 cr in Q2 FY25; highest ever quarterly EBITDA
H1 FY26 EBITDA₹208 cr, +20% YoY
EBITDA margin30% for the quarter and H1; +4 ppt YoY for Q2, +3 ppt YoY for H1
PAT₹44 cr for the quarter; ₹91 cr for H1, surpassing full-year FY25 PAT of ₹78 cr
Adjusted ROCE (excl. biologics and NBE)~17% in H1 FY26, improved from 4% in FY23
Non-captive API revenue₹205 cr
Formulation revenue₹109 cr, +16% YoY
Formulation base business growth (excl. licensing)~60% YoY for the quarter, 67% for H1
Biologics revenue₹25 cr in Q2, ₹61 cr in H1
Total service income (licensing and CDMO)₹72 cr; ₹46 cr from Formulation, ₹26 cr from API and Biologics (per an analyst's math)
H1 FY26 capex₹153 cr
Remaining FY26 capex estimate₹75–100 cr